Prostate cancer is a kind of cancer commonly found among men. A well-known hallmark of cancer is changes in protein glycosylation, which is related to the differential expression of enzymes. The changed expression of the enzymes promoted cancer cells to produce glycoproteins with specific cancer-related aberrations in glycan structures. Glycoproteins are often considered as prognostic biomarkers for monitoring tumor progression and predictive biomarkers for disease recurrence. Prostate-specific antigen is the biomarker that is used most frequently for prostate cancer detection. Extensive glycosylation changes in prostate cancer cells, including increased sialylation and fucosylation, can alter protein function and play key roles in many important biological processes in cancer, including cell signaling, adhesion, migration, and cellular metabolism.
CD BioGlyco has an expert team with strong scientific research capabilities and an advanced technology platform. With constant collaboration and innovation, CD BioGlyco provides Cancer Glycogene Discovery Services to support cancer glycogene research. We provide some glycan biomarkers and their detection methods for prostate cancer.
Fig.1 Glycogene discovery service in prostate cancer. (CD BioGlyco)
CD BioGlyco has enriched the Glycogenomics Platform to cover our customer's essential needs. In addition, our expert team has extensive experience in Glycogene Editing and Glycogene Delivery. Welcome to feel free to contact us for custom service. We look forward to your happy cooperation.